To: All North Carolina Clinicians and Laboratories  
From: Erica Wilson, MD, MPH, Medical Epidemiologist  
         Scott Shone, PhD, HCLD(ABB), Public Health Laboratory Director  
Re: Person-to-Person Monkeypox Transmission in Multiple Countries  
Date: July 14, 2022 (5 pages – replaces version dated July 12, 2022)

This memo is intended to provide an update regarding the prevention of monkeypox and the evaluation and response to possible cases. Key updates include expanded testing availability, vaccine eligibility, and treatment information.

Background:

Since May 2022, Monkeypox virus infections have been identified outside of endemic regions, including the United States, in individuals with no travel history to endemic regions. Many recent cases have been identified predominantly in gay, bisexual or other men who have sex with men (MSM) and transgender persons, although it’s important to note that monkeypox can affect anyone and infectious diseases do not tend to remain only within specific sexual or social networks.

A toolkit with educational materials to help communities understand monkeypox is available at https://epi.dph.ncdhhs.gov/cd/diseases/monkeypox/toolkit.html.

Clinical Features:

Monkeypox may present with a prodrome of flu-like symptoms and lymphadenopathy followed in 2-3 days by a rash that progresses from macular to papular to vesicular, then pustular, and then scabbing over and resolving over a period of 2-4 weeks. The prodrome may also appear simultaneously with the rash or not at all. Lesions are well circumscribed, deep seated, and often develop umbilication. Lesions may be disseminated or localized and may present in the perianal or genital area, face, mouth, and/or palms and soles. During this outbreak, some cases have presented with proctitis, anal pain, rectal lesions, and tenesmus.

Monkeypox virus can be spread person-to-person through contact with body fluids or lesions, items that have been in contact with fluids or lesions, and respiratory droplets. Zoonotic transmission has not been identified in the current outbreak. The incubation period is usually 7-14 days but can range from 5-21 days. People with monkeypox are infectious from the start of symptoms until the lesions heal and new skin forms underneath scabs.
Testing and Reporting:

Any suspected cases of monkeypox should immediately be reported to your local health department or to the Communicable Disease Branch Epidemiologist on Call at 919-733-3419. The NC Division of Public Health (NCDPH) is available to assist with monkeypox evaluation and testing, and with implementation of public health interventions to prevent further spread. Testing is widely available and there is no shortage of testing capability. Testing can be performed through the NC State Laboratory of Public Health (NCSLPH). Providers must call (919-733-3419) before sending samples to the NCSLPH. This will provide clinical consultation, guidance on proper collection and sample submission, and facilitate prioritization of specimens for processing. Testing is also now available commercially, including through LabCorp, Quest Diagnostics, and Aegis Science. Other commercial laboratories are planning to offer testing in the coming days and weeks. Some academic health centers are also developing testing capability. Testing at laboratories other than SLPH does not require a call to public health before testing. However, suspected cases must still be reported to your Local Health Department or NCDPH (919-733-3419) within 24 hours per the NC State Administrative Code.

North Carolina providers should consider monkeypox in all patients presenting with a clinically consistent picture. Molecular testing for varicella or other illnesses may be considered for patients in whom a monkeypox diagnosis is suspected, but this testing should not delay report to public health. Additional guidance is available from the CDC Health Advisory posted June 14, 2022.

Suspicion for monkeypox should be heightened if the rash occurs in a person who reports any of the following in the 21 days prior to symptom onset:
1) Having contact with a person or people who have a similar appearing rash or received a diagnosis of confirmed or suspected monkeypox OR
2) Had close or intimate in-person contact with person(s) in a social network experiencing monkeypox infections. This includes MSM who meet partners through an online website, app, or social event OR
3) Has recently returned from travel to an endemic area.

Infection Prevention:

When monkeypox is suspected, healthcare workers should implement contact and enhanced droplet or airborne precautions (if performing aerosolizing procedures), including gloves, protective gown, eye protection, and surgical mask or NIOSH-approved N95 or higher-level respirator for aerosolizing procedures. Respirators should not be re-used between patients because fomite transmission is possible. For people with monkeypox who do not require hospitalization, home isolation is required during the infectious period. Cleaning processes for testing facilities are similar to standard cleaning after a standard patient visit. See: CDC Infection Control in Healthcare Settings.

Vaccination:

The U.S. government has stockpiled two vaccines — JYNNEOS and ACAM2000 — that can prevent monkeypox in people who have been exposed to the virus if given soon after exposure. In the United States, there is currently a limited supply of JYNNEOS, although more is expected in coming weeks and months. There is an ample supply of ACAM2000; however, this vaccine should not be used in
people who have some health conditions, including a weakened immune system, skin conditions like atopic dermatitis/eczema, or pregnancy.

All available JYNNEOS doses have been allocated to states to give to people with known or suspected exposure to monkeypox. This includes:

- People who have been in close physical contact with someone diagnosed with monkeypox,
- or
- Men who have sex with men or transgender individuals who have had multiple or anonymous sex partners in the last 14 days

Information for the public about vaccine eligibility and access is available here. Supplies and eligibility criteria are expected to expand over the coming weeks. Providers interested in obtaining vaccine can request access from NC DHHS using this request form.

Treatment:

At this time there are no specific treatments approved for monkeypox infection, but tecovirimat (TPOXX), vaccinia immune globulin (VIG), and cidofovir can be considered and are available from the strategic national stockpile. Particular consideration for these options should be taken if the patient has immunocompromising conditions, lesions in the throat, eyes, or perirectal area, or the patient is a pregnant person or child. For information on these therapeutics, please see: Treatment Information for Healthcare Professionals | Monkeypox | Poxvirus | CDC. Providers interested obtaining monkeypox therapeutics must request them through NC DHHS using this request form. Additional information on ordering and prescribing therapeutics is available under resources on the North Carolina Monkeypox website.

NCSLPH Specimen Collection and Testing Guidelines:

Providers must call (919-733-3419) before sending samples to the NCSLPH. This will provide clinical consultation, guidance on proper collection and sample submission, and facilitate prioritization of specimens for processing.

State Testing Employed

The NCSLPH Bioterrorism and Emerging Pathogens (BTEP) Unit has validated the CDC Orthopox, Non-variola Orthopox, and Variola real-time PCR (RT-PCR) assays. When positive results are derived from the non-variola orthopox assay, the duplicate specimen may be sent to CDC for DNA characterization that includes monkeypox specific testing.

- Estimated turn-around time for initial results at NCSLPH is 6 to 72 hours from time of specimen receipt but may vary depending on the number of specimens received.

- USE STANDARD, CONTACT, AND DROPLET PRECAUTIONS WHEN COLLECTING SPECIMENS FOR MONKEYPOX TESTING: https://www.cdc.gov/poxvirus/monkeypox/clinicians/prep-collection-specimens.html
• Duplicate specimens (i.e. swabs of lesion fluid) must be collected simultaneously and sent to NCSLPH. One specimen from each set will be used for testing at NCSLPH; the second specimen will be sent to CDC, as needed.

### Specimens for Orthopox RT-PCR Testing

**NOTE:** At least two lesions should be sampled, preferably from different locations on the body. To allow for further characterization at CDC, **TWO DRY SWABS** should be used simultaneously to vigorously scrub each lesion.

<table>
<thead>
<tr>
<th>Disease Stage</th>
<th>Acceptable Specimen Types</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macules / Papules / Vesicles / Pustules</td>
<td>Vigorously scrub, using <strong>TWO DRY SWABS</strong>, the lesion base/lesion fluid</td>
</tr>
</tbody>
</table>

### Specimen Collection Guidance:

- Place each specimen in individual **EMPTY** collection tube (i.e., one tube per swab).
- Label each specimen tube separately with:
  - **Specimen site / type**
  - Patient name
  - Date of birth
  - Date of collection

**Swab collection** - (lesion fluid)— sterile nylon, polyester, or Dacron swabs with a plastic, wood, or thin aluminum shaft. **Do not use cotton or other types of swabs.** **Dry swabs will be processed for molecular detection; do not add transport media.** Unroofing the lesion is not required if the lesion is vigorously scrubbed, but may provide better results. To unroof the lesion:

1. Use a disposable scalpel (or a sterile 26 Gauge needle) to open and remove the top of the vesicle or pustule (do not send the scalpel or needle).
2. Taking **TWO** sterile nylon, polyester or Dacron swabs, simultaneously use both to vigorously swab the base of the lesion.
3. Break off the end of each swab separately into **EMPTY** screw-capped plastic aliquot tubes without any preservative. **DO NOT ADD ANY TRANSPORT MEDIA.**

### Specimen Storage and Shipping Requirements:

- Within one hour of collection, place all specimens in a 2-8°C refrigerator or a freezer at -20°C or colder.
- Refrigerated (2-8°C) samples are acceptable for testing up to 7 days after collection. **Frozen samples** (-20°C or lower) are acceptable for testing for up to 1 month after collection.
- Shipment to NCSLPH—If shipment is to be received at NCSLPH within 5 days of collection, specimens must be received cold (2-8°C, packaged with frozen cold packs) to be acceptable for testing. For delays exceeding 5 days, freeze specimens at -70°C & ship on dry ice to be received at NCSLPH frozen (-20°C or lower).
- Specimens must be packaged with cold packs to ensure an arrival temperature between 2 - 8°C if refrigerated and -20°C or lower if frozen. Packages should be shipped to NCSLPH as
Category B. Category B shipping instructions can be found here: Cat B Poster_v3 (dot.gov). However, please note that specimens must be packaged with frozen cold packs. If you have questions regarding Category B shipping, please contact the BTEP Unit using the information below.

- The following supplies are necessary for Cat B shipping: a rigid package with insulation, frozen ice packs, appropriate Category B labels, and a leakproof container. Specimens can be placed into (this can be a larger sample container or a specimen bag).

All specimen submissions must have a completed BTEP Specimen Submission Form.

THE BTEP UNIT MUST BE CONTACTED (919-807-8600) PRIOR TO ANY SHIPMENT OR IF YOU HAVE QUESTIONS.

Other Testing:
In addition to specimens for monkeypox testing, specimens can be collected and submitted to SLPH for VZV/HSV and syphilis, but must be accompanied by the appropriate specimen submission form(s). Unlike swabs being tested for orthopox/monkeypox, HSV and VZV tests require viral transport media.

Additional information from NCDHHS and CDC:

NCDHHS monkeypox information:
https://epi.dph.ncdhhs.gov/cd/diseases/monkeypox.html

CDC Monkeypox outbreak information:
https://www.cdc.gov/poxvirus/monkeypox/response/2022/index.html

CDC Monkeypox vaccine information:
https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html

COCA call for clinicians about the monkeypox outbreak:
https://emergency.cdc.gov/coca/calls/2022/callinfo_052422.asp

Selected scientific publications:

Monkeypox Outbreak — Nine States, May 2022. FS Minhaj et. al.
https://www.cdc.gov/mmwr/volumes/71/wr/mm7123e1.htm

Community transmission of monkeypox in the United Kingdom, April to May 2022. R Vivancos et. al.
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.22.2200422

The Detection of Monkeypox in Humans in the Western Hemisphere. KD Reed et. al.

Monkeypox Genital Lesions. R. Patrocinio-Jesus et. al.